← Back to patent-cliff list
Lumipodlin
Tier C — Watch / tradeLumipodlin
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：PD-L1
Indications (approved)：Sarcoma, Hepatocellular carcinoma, Non-small cell lung cancer, Urothelial carcinoma, Solid tumour, Oesophageal cancer
Regional status
US
-
EU
-
China
Phase II
2024-11-13
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Lumipodlin?
Approved indications include: Sarcoma, Hepatocellular carcinoma, Non-small cell lung cancer, Urothelial carcinoma, Solid tumour, Oesophageal cancer.
When does the Lumipodlin patent expire?
No public expiry year is available for Lumipodlin yet; this page updates once verified.
How do I get a quote for Lumipodlin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01